Long-term treatment outcomes of temozolomide-based chemoradiation in patients with adult-type diffuse IDH-mutant grade 2 astrocytoma

[1] Louis DN(2021)The 2021 WHO classification of tumors of the Central Nervous System: a summary Neuro Oncol 23 1231-1251

[2] Perry A(2021)EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood Nat Rev Clin Oncol 18 170-186

[3] Wesseling P(2012)Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802 J Clin Oncol 30 3065-3070

[4] Brat DJ(2016)Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma N Engl J Med 374 1344-1355

[5] Cree IA(2015)Phase 2 study of temozolomide-based chemoradiation therapy for high-risk low-grade gliomas: preliminary results of Radiation Therapy Oncology Group 0424 Int J Radiat Oncol Biol Phys 91 497-504

[6] Figarella-Branger D(2020)Comprehensive genomic analysis in NRG Oncology/RTOG 9802: a phase III trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma J Clin Oncol 38 3407-3417

[7] Hawkins C(2020)Phase 2 study of a temozolomide-based chemoradiation therapy regimen for High-Risk, Low-Grade Gliomas: long-term results of Radiation Therapy Oncology Group 0424 Int J Radiat Oncol Biol Phys 107 720-725

[8] Ng HK(2011)Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas Lancet Oncol 12 583-593

[9] Pfister SM(2021)Evidence-based recommendations on categories for extent of resection in diffuse glioma Eur J Cancer 149 23-33

[10] Reifenberger G(2016)Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033–26033): a randomised, open-label, phase 3 intergroup study Lancet Oncol 17 1521-1532

[1] Louis DN(2021)The 2021 WHO classification of tumors of the Central Nervous System: a summary Neuro Oncol 23 1231-1251

[2] Perry A(2021)EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood Nat Rev Clin Oncol 18 170-186

[3] Wesseling P(2012)Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802 J Clin Oncol 30 3065-3070

[4] Brat DJ(2016)Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma N Engl J Med 374 1344-1355

[5] Cree IA(2015)Phase 2 study of temozolomide-based chemoradiation therapy for high-risk low-grade gliomas: preliminary results of Radiation Therapy Oncology Group 0424 Int J Radiat Oncol Biol Phys 91 497-504

[6] Figarella-Branger D(2020)Comprehensive genomic analysis in NRG Oncology/RTOG 9802: a phase III trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma J Clin Oncol 38 3407-3417

[7] Hawkins C(2020)Phase 2 study of a temozolomide-based chemoradiation therapy regimen for High-Risk, Low-Grade Gliomas: long-term results of Radiation Therapy Oncology Group 0424 Int J Radiat Oncol Biol Phys 107 720-725

[8] Ng HK(2011)Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas Lancet Oncol 12 583-593

[9] Pfister SM(2021)Evidence-based recommendations on categories for extent of resection in diffuse glioma Eur J Cancer 149 23-33

[10] Reifenberger G(2016)Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033–26033): a randomised, open-label, phase 3 intergroup study Lancet Oncol 17 1521-1532